Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DC-CIK cells (Pell Bio-Med Technology)
- Development stage
- Unknown
- Lead developer
- Pell Bio-Med Technology
- Modality
- Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Administration
- Intravenous
01
Overview
Pell Bio-Med Technology's DC-CIK cell therapy is an autologous adoptive cell immunotherapy that combines dendritic cells (DCs) with cytokine-induced killer (CIK) cells. This dual-component approach leverages the antigen-presenting capabilities of DCs to prime and activate CIK cells, which are a heterogeneous population of ex-vivo expanded T-effector cells (CD3+CD56+) possessing both T-cell and natural killer (NK) cell properties. The therapy aims to enhance anti-tumor immune responses through both MHC-restricted and non-MHC-restricted cytotoxicity. It is currently utilized in Taiwan under the Regulations of Special Medical Techniques for various cancer indications.
- Other names
- dendritic cell-activated CIK cellsDC-CIK cell therapydendritic cell-activated cytokine-induced killer cellsDC-CIK (商業產品)
Beyond the preview
Go deeper on DC-CIK cells (Pell Bio-Med Technology).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DC-CIK cells (Pell Bio-Med Technology).